NSPR
$1.79
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific.
Recent News
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +41.48% and +2.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
InspireMD Inc (NSPR) Q3 2025 Earnings Call Highlights: Robust Revenue Growth Amid Rising Expenses
InspireMD Inc (NSPR) reports a 39% revenue increase driven by the US launch of CGuard Prime, despite a widened net loss and increased operating expenses.
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
InspireMD (NSPR) delivered earnings and revenue surprises of 0.00% and +31.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?